Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Update

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 3,670,000 shares, an increase of 7.9% from the October 15th total of 3,400,000 shares. Based on an average trading volume of 443,400 shares, the days-to-cover ratio is currently 8.3 days. Currently, 6.4% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a research report on Friday, August 9th.

Aldeyra Therapeutics Stock Performance

ALDX traded down $0.06 during trading on Friday, hitting $4.21. The company's stock had a trading volume of 625,242 shares, compared to its average volume of 449,206. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18. The firm's 50 day moving average price is $5.45 and its two-hundred day moving average price is $4.60. Aldeyra Therapeutics has a 12 month low of $2.43 and a 12 month high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.25). Sell-side analysts predict that Aldeyra Therapeutics will post -0.89 EPS for the current fiscal year.

Institutional Trading of Aldeyra Therapeutics

Several hedge funds have recently modified their holdings of ALDX. US Bancorp DE acquired a new stake in Aldeyra Therapeutics in the third quarter worth about $30,000. SG Americas Securities LLC acquired a new stake in shares of Aldeyra Therapeutics during the 2nd quarter worth approximately $38,000. Diversified Trust Co acquired a new position in Aldeyra Therapeutics in the second quarter valued at approximately $41,000. Laidlaw Wealth Management LLC grew its holdings in Aldeyra Therapeutics by 32.6% during the 2nd quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 4,150 shares during the period. Finally, Paloma Partners Management Co acquired a new position in shares of Aldeyra Therapeutics in the 3rd quarter valued at $62,000. 59.71% of the stock is owned by institutional investors.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.